IPATHER
Clinical Trial Program
A phase Ib study of Ipatasertib, an AKT inhibitor, in combination with Pertuzumab plus Trastuzumab in patients with PI3KCA-mutant, HER2-positive locally advanced or metastatic breast cancer
Phase I
Status
Recruiting
Tumour subtype:
HER2+
Scenario
Locally Advanced or Metastatic
Sites
HOSPITAL CLÍNICO UNIV. SANTIAGO DE COMPOSTELA, HOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, HOSPITAL UNIVERSITARIO MADRID SANCHINARRO (CENTRO INTEGRAL ONCOLÓGICO CLARA CAMPAL (CIOCC)), HOSPITAL UNIVERSITARIO VIRGEN DE LA MACARENA, HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, ICO BADALONA, INSTITUTO VALENCIANO DE ONCOLOGÍA, HOSPITAL DEL MAR
